西格列汀与阿卡波糖治疗初发2型糖尿病的疗效及安全性比较

孙鹃鹏

（陕西省咸阳市永寿县人民医院，陕西 咸阳，713400）

浏览次数：319次 下载次数：354次

摘要：

目的 探讨西格列汀与阿卡波糖治疗初发2型糖尿病的疗效及安全性。方法 收集我院2014年9月至2016年9月收治的初发2型糖尿病的患者70例作为本次研究对象，按照随机数字表法分为观察组和对照组，每组35例，观察组患者口服西格列汀，对照组患者口服阿卡波糖。比较两组患者治疗后的空腹血糖（FPG）、餐后2 h 血糖（2h PG）、糖化血红蛋白（HbAlc）及 服药后的不良反应发生情况。结果 治疗后，观察组的FPG［（5.33±1.46）mmoL/L］低于对照组［（6.45±0.76）mmoL/L］，观察组2 h PG ［（8.67±1.52）mmoL/L］低于对照组［（9.73±1.64）mmoL/L］，观察组HbAlc ［（6.32±0.54）%］低于对照组［（7.21± 0.84）%］，差异均有统计学意义（P<0.05）。观察组患者的不良反应总发生率为2.86%低于对照组的不良反应总发生率 14.29%，差异具有统计学意义（P<0.05）。结论 西格列汀治疗初发2型糖尿病的疗效及安全性优于阿卡波糖，可显著降低糖尿病患者并发症的发生率，提高了患者的生活质量，服药简单、方便，可在临床推广使用。

关键词：西格列汀；阿卡波糖；初发2 型糖尿病

中图分类号：R587.1文献标志码：A文章编号：2096-1413(2017)30-0031-02

Efficacy and safety comparison of sitagliptin and acarbose in the treatment of newly diagnosed type 2 diabetes mellitus
SUN Juan-peng
(People``s Hospital of Yongshou County, Xianyang 713400, China)

ABSTRACT: Objective To evaluate the efficacy and safety of sitagliptin and acarbose in the treatment of newly diagnosed type 2 diabetes mellitus. Methods Seventy patients with newly diagnosed type 2 diabetes mellitus admitted in our hospital from September 2014 to September 2016 were selected and divided into the observation group (35 patients who were given sitagliptin) and the control group (35 patients who were given acarbose) according to the method of random number table. The levels of FPG, 2 h PG, HbAlc and adverse reactions after treatment were compared between the two groups. Results After treatment, the FPG [(5.33±1.46) mmoL/L] in the observation group was lower than that in the control group [(6.45±0.76) mmoL/L], and the 2 h PG [(8.67±1.52) mmoL/L] in the observation group was lower than that of the control group (9.73±1.64) mmoL/L], and HbAlc [(6.32±0.54) %] in the observation group was lower than that in the control group [(7.21±0.84) % ], the differences were statistically significant (P<0.05). The incidence of adverse reactions was 2.86% in the observation group, which was lower than 14.29% of the control group, the difference was statistically significant (P<0.05). Conclusion Sitagliptin in the treatment of newly diagnosed type 2 diabetes mellitus is superior to acarbose in the curative effect and safety, which can significantly reduce the incidence of complications in diabetic patients and improve the quality of life of the patients. The medication is simple and convenient and can be popularized in clinic.
KEYWORDS: sitagliptin; acarbose; newly diagnosed type 2 diabetes mellitus

参考文献：
[1] 郭伟宏,赵灿,李红梅.西格列汀联合阿卡波糖治疗初发2型糖尿病临床研究[J].现代中西医结合杂志,2014,23(11):1187-1188.
[2] 吴心池,唐伟,方铭,等.西格列汀和阿卡波糖对初发2 型糖尿病降糖作用的比较[J].中国社区医师:医学专业,2014,15(21):15-16.
[3] 包亚明,陈干明.阿卡波糖与西格列汀治疗2 型糖尿病的疗效及对胃肠道相关激素的影响[J].实用药物与临床,2014,17(8):966-969.
[4] 蒋丽敏,梁琳琅,李萍.西格列汀联合甘精胰岛素在初发重症2型糖尿病胰岛素泵强化治疗后的应用效果[J].中国医药指南,2015,13(26):68-69.
[5] LI CJ,LIU XJ,BAI L,et al.Efficacy and safety of vildagliptin, saxagliptin or sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents[J].Diabetol Metab Syndr,2014,6:69.
[6] 郭伟宏,赵灿,李红梅.西格列汀联合阿卡波糖治疗初发2 型糖尿病临床研究[J].现代中西医结合杂志,2014,23(11):1187-1188.
[7] 包亚明,陈干明.阿卡波糖与西格列汀治疗2 型糖尿病的疗效及对胃肠道相关激素的影响[J].实用药物与临床,2014,17(8):966-969.
[8] 李庆玲.西格列汀与阿卡波糖对初发2 型糖尿病的疗效比较和胃 肠道相关激素的影响研究[J].糖尿病新世界,2014,16(21):3-4.